Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Recent & Breaking News (NDAQ:SNDX)

Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

PR Newswire December 19, 2023

Syndax Announces Pricing of $200 Million Public Offering of Common Stock

PR Newswire December 14, 2023

Syndax Announces Proposed $150 Million Public Offering of Common Stock

PR Newswire December 14, 2023

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

PR Newswire December 12, 2023

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

PR Newswire December 11, 2023

Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting

PR Newswire December 4, 2023

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire December 1, 2023

Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting

PR Newswire November 21, 2023

Syndax Announces Participation at Stifel Healthcare Conference

PR Newswire November 7, 2023

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire November 3, 2023

Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

PR Newswire November 2, 2023

Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting

PR Newswire November 2, 2023

Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

PR Newswire November 2, 2023

Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023

PR Newswire October 26, 2023

Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program

PR Newswire October 24, 2023

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 6, 2023

Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

PR Newswire October 2, 2023

Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023

PR Newswire September 29, 2023

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire September 1, 2023

Syndax Announces Participation at the Citi 18th Annual BioPharma Conference

PR Newswire August 31, 2023